Share Name Share Symbol Market Type Share ISIN Share Description
Bb Healthcare Trust Plc LSE:BBH London Ordinary Share GB00BZCNLL95 RED ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 1.73% 200.00 198.00 198.40 198.60 195.00 195.00 1,938,461 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.7 1.1 0.1 1,428.6 1,104

Bb Healthcare Share Discussion Threads

Showing 26 to 42 of 100 messages
Chat Pages: 4  3  2  1
Dave - thanks for the information on that. I did see the IPO announced, but neither of my two brokers was participating. If you're old enough, you might remember the two Slater-Walker Dual Investment Trusts from the 1970s which were nicknamed "The Dustbins". I won't be investing either.
Last week I did invest in this IPO but (at risk of going off topic)let me warn any like minded IPO investors that I will not be investing in this weeks IPO which is another investment trust called RM Direct lending. Thirty years ago I joined a private company which operated a bit like Dragons Den. Well connected city grandees had started investing their own family fortunes and friends money in loans to smaller companies and created a ragbag portfolio. This weeks float is very similar, an investment manager has a seed portfolio ready to be injected into the new float money. My employers were in trouble, there were dud loans all over the place and no way of unloading them so they floated an investment trust and dumped all their rubbish in it. Within a year the trust was in trouble and a lot of private investors lost their money. I do not for one moment suggest that this weeks float has any connection whatsoever with my story, but the sense of deja vu was enough to scare me off.
essential - I think also the idea is to be able to offer new 'C' shares which will eventually merge with the ords. That would most likely happen if the shares went to a premium ... which appears to be happening now!
Made my first purchase this morning. I like the mechanism to ensure the price does not drop to a discount. Every portfolio needs exposure to this sector IMHO
Thanks for setting up this thread jonwig. I'm now looking to hold long term, the 3.5% div helps me to just leave it alone in my sipp and give it 3 or 4 years to see what happens. KT.
Article and video: Http://citywire.co.uk/money/bb-healthcare-we-wont-buy-price-gougers/a975223?ref=citywire-money-latest-news-list
Friday 2nd isn't it, Molby? £150m vs target £200m - seems private investors weren't over keen here.
Thanks Jonwig, you give me a degree of comfort but also a new worry, the Trump effect. Recently one of the doomsters said that the Trump effect might well emulate the Ronald Regan era in which the market rose as he took office, peaked in April and then fell by 20% by September. I think I will buy, expect to top up in late 2017 and then wait 5 years for the reward.
Hi, Dave - you caught me just as I was off to cook lunch, so quickly ... Healthcare, pharma might get a boost from Trump (ie. non-Clinton) and the Trump rally still has some way to go I think. Paying divis out of capital, share buybacks and annual redemption should limit the downside. Track record of managers in an existing fund looks good. Charges not excessive and no performance fee. Like you I'm very cautious at present with lots of cash and short-dated gilts, but I shall apply for some. By the way I haven't trawled through the prospectus!!
jaws - I didn't know they'd tried before. Thanks.
They tried last year twice to pull IPO at last minute.there is few other which trades at discount like BIOG. will try to get more discout link later when I can.
Cheers - I've copied that to the header. I'm inclined to invest here, there's a lot of attractive features in the way it's set up.
Thanks for setting the thread up, jonwig. Here's the prospectus for further details... HTTP://www.bbhealthcaretrust.com/index.php?eID=tx_nawsecuredl&u=12&g=1&t=1479337412&hash=00e341cc10485c5e0362086233d8e7bd351c4ae6&file=fileadmin/user_upload/files/bbhealthcaretrust/Prospectus.pdf
This isn't a sector I know much about. Would welcome any views. Discount and redemption policy looks useful. My broker's deadline is 28 Nov. Minimum 1,000 shs @ 100p.
. Http://www.bbhealthcaretrust.com . IPO to close at end of month. £200m at 100p. From the factsheet: • To provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies • Specific return objectives are: (i) to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3 year period (the index total return including dividends reinvested on a net basis); and (ii) to seek to generate a double-digit total shareholder return per annum over a rolling 3 year period • Target total dividend in the first financial period is 3.5p per ordinary share (to be paid mostly out of capital); target annual dividend in subsequent financial years set at 3.5% of preceding financial year end NAV (to be paid mostly out of capital and in two equal instalments) Summary investment policy • BB Healthcare intends to invest in a concentrated portfolio of listed or quoted equities in the global healthcare industry (maximum of 35 holdings) • The investable universe for BB Healthcare is the global healthcare industry including companies within industries such as pharmaceuticals, biotechnology, medical devices and equipment, healthcare insurers and facility operators, information technology (where the product or service supports, supplies or services the delivery of healthcare), drug retail, consumer healthcare and distribution • There will be no restrictions on the constituents of BB Healthcare’s portfolio by index benchmark, geography, market capitalisation or healthcare industry sub-sector. BB Healthcare will not seek to replicate the benchmark index in constructing its portfolio. Link to Prospectus: HTTP://www.bbhealthcaretrust.com/index.php?eID=tx_nawsecuredl&u=12&g=1&t=1479337412&hash=00e341cc10485c5e0362086233d8e7bd351c4ae6&file=fileadmin/user_upload/files/bbhealthcaretrust/Prospectus.pdf Significant Holdings (total 253,911,268 shares after second issue): Heartwood W M ....... 10,813,202 4.2% Erich Hunziker ...... 10,000,000 3.9% Schroders ............ 8,064,100 3.2% Whale Holding AG ..... 3,525,000 1.5% Net asset values (monthly): 02/12/16 ... 98.28p 03/01/17 .. 103.55p 28/02/17 .. 112.3p 31/03/17 .. 110.6p 30/04/17 .. 111.4p 31/05/17 .. 110.2p
.S. Stocks Drop on Genentech Shortfall; Microsoft Declines July 12 (Bloomberg) -- U.S. stocks fell as a sales report from Genentech Inc. increased concern that earnings will trail analyst estimates. Genentech, the world's second-largest biotechnology company, dropped after revenue from colon-cancer treatment Avastin fell short of investor expectations. Brunswick Corp. declined after the boat maker said 2006 profit will decline. ``The concern really is: Can earnings growth continue?'' said Larry Peruzzi, a senior equity trader at Boston Co. in Boston. Investors are ``very cautious.'' The Standard and Poor's 500 Index lost 1.84, or 0.1 percent, to 1270.68 at 10:17 a.m. in New York. The Dow Jones Industrial Average fell 15.77, or 0.1 percent, to 11,119. The Nasdaq Composite Index dropped 9.16, or 0.4 percent, to 2119.70, dragged down by Microsoft Corp. Genentech's sales, along with shortfalls from Alcoa Inc. and Lucent Technologies Inc., raised concern that economic and earnings growth may slow. Investors are also wary higher interest rates may be cutting into profits. Analysts expect S&P 500 companies to report 12.3 percent growth in earnings for the April-to-June period, based on a survey by Thomson Financial. The Federal Reserve has raised interest rates 17 times over two years to 5.25 percent. Genentech's Miss Genentech lost $2.26 to $81.80. U.S. sales of Avastin totaled $423 million during the second quarter. That was less than what investors were expecting, according to Cowen & Co. analyst Eric Schmidt. Profit rose 79 percent as doctor's prescribed more of the company's medicines. Deutsche Bank AG and Prudential Equity Group Inc. both downgraded the company's stock. . . Genentech and Brunswick became the latest companies to disappoint investors. Alcoa, the world's largest aluminum producer, said second-quarter profit fell short of analyst estimates and record earnings aren't sustainable. Lucent said sales and profit missed analyst estimates.
Symb Company Name===== $Price Weight DNA- Genentech Inc.. : $44.00 32.19% AMGN Amgen Inc...... : $64.48 27.42% BIIB Biogen Idec Inc : $26.95. 9.94% GILD Gilead Sciences : $16.00. 6.17% CHIR Chiron Corp.... : $16.00. 5.12% GENZ Genzyme Corp... : $14.00. 4.59% ==== Sub-Totals===== : ...... 85.43% Others: Applera - Appl.Biosystems ABI 18.00 2.56% MedImmune Inc........... MEDI 15.00 2.55% Sepracor Inc............ SEPR. 6.00 1.95% Millennium Pharmaceutic. MLNM 12.00 1.48% Shire Pharmaceuticals.. SHPGY. 6.83 1.41% ICOS Corp............... ICOS. 4.00 1.07% Affymetrix Inc.......... AFFX. 4.00 0.92% Qlt Inc................. QLTI. 5.00 0.82% Human Genome Sciences... HGSI. 8.00 0.67% Alkermes Inc............ ALKS. 4.00 0.41% Applera - Celera Genomics CRA. 4.00 0.40% Enzon Inc............... ENZN. 3.00 0.33%
Chat Pages: 4  3  2  1
ADVFN Advertorial
Your Recent History
Bb Healthc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210920 00:23:27